Literature DB >> 29808926

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

Donal P McLornan1, Richard Szydlo2, Marie Robin3, Anja van Biezen4, Linda Koster4, Henrik J P Blok4, Maria T Van Lint5, Jürgen Finke6, Antonin Vitek7, Kristina Carlson8, Laimonas Griskevicius9, Ernst Holler10, Maija Itälä-Remes11, Michel Schaap12, Gerard Socié3, Jacques-Olivier Bay13, Yves Beguin14, Benedetto Bruno15, Jan J Cornelissen16, Tobias Gedde-Dahl17, Per Ljungman18, Marie T Rubio19, Ibrahim Yakoub-Agha20, Evgeny Klyuchnikov21, Eduardo Olavarria2, Yves Chalandon22, Nicolaus Kröger21.   

Abstract

Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.
© 2018 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  JAK inhibitors; allogeneic stem cell transplant; fibrosis; mylelofibrosis; relapse

Mesh：

Year:  2018        PMID： 29808926     DOI： 10.1111/bjh.15407

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  7 in total

1.  Survival following allogeneic transplant in patients with myelofibrosis.

Authors:  Krisstina Gowin; Karen Ballen; Kwang Woo Ahn; Zhen-Huan Hu; Haris Ali; Murat O Arcasoy; Rebecca Devlin; Maria Coakley; Aaron T Gerds; Michael Green; Vikas Gupta; Gabriela Hobbs; Tania Jain; Malathi Kandarpa; Rami Komrokji; Andrew T Kuykendall; Kierstin Luber; Lucia Masarova; Laura C Michaelis; Sarah Patches; Ashley C Pariser; Raajit Rampal; Brady Stein; Moshe Talpaz; Srdan Verstovsek; Martha Wadleigh; Vaibhav Agrawal; Mahmoud Aljurf; Miguel Angel Diaz; Belinda R Avalos; Ulrike Bacher; Asad Bashey; Amer M Beitinjaneh; Jan Cerny; Saurabh Chhabra; Edward Copelan; Corey S Cutler; Zachariah DeFilipp; Shahinaz M Gadalla; Siddhartha Ganguly; Michael R Grunwald; Shahrukh K Hashmi; Mohamed A Kharfan-Dabaja; Tamila Kindwall-Keller; Nicolaus Kröger; Hillard M Lazarus; Jane L Liesveld; Mark R Litzow; David I Marks; Sunita Nathan; Taiga Nishihori; Richard F Olsson; Attaphol Pawarode; Jacob M Rowe; Bipin N Savani; Mary Lynn Savoie; Sachiko Seo; Melhem Solh; Roni Tamari; Leo F Verdonck; Jean A Yared; Edwin Alyea; Uday Popat; Ronald Sobecks; Bart L Scott; Ryotaro Nakamura; Ruben Mesa; Wael Saber
Journal:  Blood Adv       Date:  2020-05-12

Review 2.  Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.

Authors:  Sophia S Lee; Srdan Verstovsek; Naveen Pemmaraju
Journal:  J Immunother Precis Oncol       Date:  2021-06-29

3.  Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.

Authors:  Juan Carlos Hernández-Boluda; Arturo Pereira; Nicolaus Kröger; Dietrich Beelen; Marie Robin; Martin Bornhäuser; Emanuele Angelucci; Antonin Vitek; Igor Wolfgang Blau; Riitta Niittyvuopio; Jürgen Finke; Jan J Cornelissen; Jakob Passweg; Peter Dreger; Eefke Petersen; Lothar Kanz; Jaime Sanz; Tsila Zuckerman; Nienke Zinger; Simona Iacobelli; Patrick Hayden; Tomasz Czerw; Donal McLornan; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2020-04-14       Impact factor: 11.528

Review 4.  Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Authors:  Donal P McLornan; Juan Carlos Hernandez Boluda; Tomasz Czerw; Nicholas Cross; H Joachim Deeg; Marcus Ditschkowski; Mufaddal T Moonim; Nicola Polverelli; Marie Robin; Mahmoud Aljurf; Eibhlin Conneally; Patrick Hayden; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2021-05-26       Impact factor: 11.528

5.  State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.

Authors:  Donal P McLornan; Ibrahim Yakoub-Agha; Marie Robin; Yves Chalandon; Claire N Harrison; Nicolaus Kroger
Journal:  Haematologica       Date:  2019-03-14       Impact factor: 9.941

Review 6.  The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.

Authors:  Mario Tiribelli; Francesca Palandri; Emanuela Sant'Antonio; Massimo Breccia; Massimiliano Bonifacio
Journal:  Bone Marrow Transplant       Date:  2019-09-18       Impact factor: 5.483

7.  Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation.

Authors:  Masahiko Sumi; Mari Kitahara; Tsutomu Shishido; Hiroko Kazumoto; Nozomu Uematsu; Takehiko Kirihara; Keijiro Sato; Toshimitsu Ueki; Yuki Hiroshima; Hikaru Kobayashi
Journal:  Intern Med       Date:  2020-07-07       Impact factor: 1.271
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.